Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Decitabine and Paclitaxel in Advanced Breast Cancer
NCT03282825Phase 1Unknown
- Sponsor
- Dongwha Pharmaceutical Co., Ltd.
- Start
- Mar 2017
- Primary completion
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of decitabine in breast cancer, sponsored by Dongwha Pharmaceutical Co., Ltd. Primary endpoints: Maximum Tolerated Dose at 4 weeks and Dose Limiting Toxicity at 4 weeks. Status: unknown.
02
Drugs
decitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03282825.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03282825.